On May 1, 2025, DCx Biotherapeutics, a preclinical-stage discovery and translational company addressing key dependencies of cancer lesions, announced an agreement with Repare Therapeutics to in-license its discovery platform and intellectual property, retain talent, and acquire laboratory facilities and equipment in Montreal. Wilson Sonsini Goodrich & Rosati advised DCx on the transaction.
 
The agreement, effective May 1, 2025, aims to enhance DCx's capabilities in developing Multi-Modal Antibody Drug Conjugates (MM-ADCs) targeting genetically-defined cancers. Repare will receive upfront cash payments, equity in DCx, a board nominee, as well as out-licensing, clinical, and commercial milestones, along with low single-digit tiered sales royalties for products developed from Acquired Programs and Acquired Targets.
 
The Wilson Sonsini team that advised DCx includes:

Technology Transactions
Farah Gerdes
Andrew Poling
Alysha (Rameshk) O’Hara
Morgan (Brown) Rhodes Logan
Mina Li
 
Corporate
Jason Breen
Amy Caiazza
Bryan King
 
Tax
Myra Sutanto Shen
 
For more information, please see DCx's news release.